Home / BUSINESS / Gufic Biosciences surges on receiving patent for parenteral formulations of Levosimendan

Gufic Biosciences surges on receiving patent for parenteral formulations of Levosimendan

Gufic Biosciences is currently trading at Rs. 69.90, up by 1.70 points or 2.49% from its previous closing of Rs. 68.20 on the BSE.

The scrip opened at Rs. 69.90 and has touched a high and low of Rs. 69.90 and Rs. 69.00 respectively.

The BSE group ‘B’ stock of face value Rs. 1 has touched a 52 week high of Rs. 98.80 on 07-Jan-2019 and a 52 week low of Rs. 51.10 on 08-Aug-2019.

Last one week high and low of the scrip stood at Rs. 70.00 and Rs. 66.40 respectively. The current market cap of the company is Rs. 530.80 crore.

The promoters holding in the company stood at 65.75%, while Institutions and Non-Institutions held 9.56% and 24.68% respectively.

Gufic Biosciences has received Patent Certificate from the Patent Office, the Government of India, for Parenteral Formulations of Levosimendan.

Gufic Biosciences is engaged in diversified business viz. Pharma, Healthcare, Bio- Technology, Seeds, Herbal etc.

Please share this news